Biomaterial Database

[Thrombosis in various diseases: myeloproliferative disorders]. 1986

H Niikura

UI	MeSH Term	Description	Entries
D009196	Myeloproliferative Disorders	Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.	Disorder, Myeloproliferative,Disorders, Myeloproliferative,Myeloproliferative Disorder
D010977	Platelet Factor 3	A phospholipid from the platelet membrane that contributes to the blood clotting cascade by forming a phospholipid-protein complex (THROMBOPLASTIN) which serves as a cofactor with FACTOR VIIA to activate FACTOR X in the extrinsic pathway of BLOOD COAGULATION.	PF 3,Factor 3, Platelet
D010978	Platelet Factor 4	A CXC chemokine that is found in the alpha granules of PLATELETS. The protein has a molecular size of 7800 kDa and can occur as a monomer, a dimer or a tetramer depending upon its concentration in solution. Platelet factor 4 has a high affinity for HEPARIN and is often found complexed with GLYCOPROTEINS such as PROTEIN C.	Antiheparin Factor,CXCL4 Chemokine,Chemokine CXCL4,Heparin Neutralizing Protein,PF4 (Platelet Factor 4),gamma-Thromboglobulin,CXCL4, Chemokine,Chemokine, CXCL4,gamma Thromboglobulin
D001779	Blood Coagulation Factors	Endogenous substances, usually proteins, that are involved in the blood coagulation process.	Clotting Factor,Coagulation Factors,Blood Coagulation Factor,Clotting Factors,Coagulation Factor,Coagulation Factor, Blood,Coagulation Factors, Blood,Factor, Coagulation,Factors, Coagulation,Factor, Blood Coagulation,Factor, Clotting,Factors, Blood Coagulation,Factors, Clotting
D002066	Busulfan	An alkylating agent having a selective immunosuppressive effect on BONE MARROW. It has been used in the palliative treatment of chronic myeloid leukemia (MYELOID LEUKEMIA, CHRONIC), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.	Busulphan,Busulfan Wellcome,Busulfex,Glyzophrol,Myelosan,Mylecytan,Myleran,Myléran,n-Butane-1,3-di(methylsulfonate),Wellcome, Busulfan
D002225	Carbazilquinone	An alkylating agent structurally similar to MITOMYCIN and found to be effective in the treatment of leukemia and various other neoplasms in mice. It causes leukemia and thrombocytopenia in almost all human patients.	Carboquinone,Carboquone,Esquinon
D004176	Dipyridamole	A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)	Antistenocardin,Apo-Dipyridamole,Cerebrovase,Cléridium,Curantil,Curantyl,Dipyramidole,Kurantil,Miosen,Novo-Dipiradol,Persantin,Persantine,Apo Dipyridamole,Novo Dipiradol
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001241	Aspirin	The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)	Acetylsalicylic Acid,2-(Acetyloxy)benzoic Acid,Acetysal,Acylpyrin,Aloxiprimum,Colfarit,Dispril,Easprin,Ecotrin,Endosprin,Magnecyl,Micristin,Polopirin,Polopiryna,Solprin,Solupsan,Zorprin,Acid, Acetylsalicylic
D001620	beta-Thromboglobulin	A platelet-specific protein which is released when platelets aggregate. Elevated plasma levels have been reported after deep venous thrombosis, pre-eclampsia, myocardial infarction with mural thrombosis, and myeloproliferative disorders. Measurement of beta-thromboglobulin in biological fluids by radioimmunoassay is used for the diagnosis and assessment of progress of thromboembolic disorders.	beta-2 Thromboglobulin,Thromboglobulin, beta-2,beta 2 Thromboglobulin,beta Thromboglobulin

Related Publications

H Niikura

Bleeding and thrombosis in myeloproliferative disorders.

September 1998, Current opinion in hematology,

H Niikura

Platelets and thrombosis in myeloproliferative diseases.

January 2005, Hematology. American Society of Hematology. Education Program,

H Niikura

[Myeloproliferative disorders in neoplastic diseases].

July 1962, Harefuah,

H Niikura

Thrombosis and hemorrhage in chronic myeloproliferative disorders.

October 1999, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis,

H Niikura

Bleeding and thrombosis in the myeloproliferative disorders.

July 1984, Blood,

H Niikura

Myeloproliferative disorders in portal vein thrombosis in adults.

September 1989, Hepatology (Baltimore, Md.),

H Niikura

Erythromelalgia in thrombocythemia of various myeloproliferative disorders.

February 1992, American journal of hematology,

H Niikura

Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation.

November 2008, Leukemia,